PRIME International Symposium, September 28-29 2026

He seemed quite aware of the criticisms of his new Rosetta Stone project design also.. whilst not really changing the approach and really didn’t make it sound exciting.
I hope Danny A wouldn't mind me saying that he told me by email a couple of months ago, in response to my inquiry, that they are very interested in the CD38 angle and will keep an eye on CD24 as well.

Charles Sherpard wrote a post a while back implying Rosetta Stone will try to replicate the 2024 IFNy long covid paper from iirc Cambridge that people on here liked.

So I think just those elements of attempting to replicate these interesting and potentially important findings make Rosetta Stone a worthwhile study.
 
He seemed quite aware of the criticisms of his new Rosetta Stone project design also.. whilst not really changing the approach and really didn’t make it sound exciting.
I just don't see the point of rerunning studies that didn't find much signal the first time. I am much more interested in running something no one else has considered, looking at things we don't currently name in blood, urine, saliva or developing antibodies for finding issue resident infections with PET. Just something, anything they has not been done yet. Because all we can say so far is nothing stands out as appearing in every patient really obviously in anything measured so far. Stop looking for your keys under the light and go make a torch and hunt where you think you dropped them.
 
I just don't see the point of rerunning studies that didn't find much signal the first time. I am much more interested in running something no one else has considered, looking at things we don't currently name in blood, urine, saliva or developing antibodies for finding issue resident infections with PET. Just something, anything they has not been done yet. Because all we can say so far is nothing stands out as appearing in every patient really obviously in anything measured so far. Stop looking for your keys under the light and go make a torch and hunt where you think you dropped them.

He said we need to do better than the other studies, it wasn't clear how this study was different to those. Maybe it's because it will have a larger sample size? But I don't think he mentioned how large the cohorts will be.
 
To be fair, Altmann seemed very aware of the need to shift focus and if, as he says and V.R.T. confirms he is working with jackie Cliff and taking an interest in CD38 and CD24 I think we may at least get some clarity on interesting data we already have.

That would be good, on his slide about the experiments they intend to do, for the pbmcs collection it only said measure glycolysis/respiration, so I hope they do more than just that
 
I'm curious what people think about the reduction in capillary lumen diameter found in long covid and mecfs compared to controls from Rob Wusts presentation. The effect size is gigantic with a blue sky separation of the cohorts. I have some memory of s4me members being skeptical of the implications though.

The Electromyography and handgrip strength experiment from the NIH intramural study appeared to show that patients experience increasing fatigue long before any actual peripheral changes/ fatigue in the muscle itself, possibly suggesting the fatigue is coming centrally and not the muscles. That might appear to conflict with what Rob Wust is arguing though maybe there are more complicated reasons why it might tally.
 
I hope Danny A wouldn't mind me saying that he told me by email a couple of months ago, in response to my inquiry, that they are very interested in the CD38 angle and will keep an eye on CD24 as well.

Charles Sherpard wrote a post a while back implying Rosetta Stone will try to replicate the 2024 IFNy long covid paper from iirc Cambridge that people on here liked.

So I think just those elements of attempting to replicate these interesting and potentially important findings make Rosetta Stone a worthwhile study.
Nice work getting in contact. And agree if they can listen, learn and adapt it’s definitely worthwhile. This was an area I thought they may be interested in but haven’t heard anything
 
To be fair, Altmann seemed very aware of the need to shift focus and if, as he says and V.R.T. confirms he is working with jackie Cliff and taking an interest in CD38 and CD24 I think we may at least get some clarity on interesting data we already have.
I'm not watching the talks live and didn't know he was working with Jackie Cliff, that's great!
 
I'm curious what people think about the reduction in capillary lumen diameter found in long covid and mecfs compared to controls from Rob Wusts presentation. The effect size is gigantic with a blue sky separation of the cohorts. I have some memory of s4me members being skeptical of the implications though.

The Electromyography and handgrip strength experiment from the NIH intramural study appeared to show that patients experience increasing fatigue long before any actual peripheral changes/ fatigue in the muscle itself, possibly suggesting the fatigue is coming centrally and not the muscles. That might appear to conflict with what Rob Wust is arguing though maybe there are more complicated reasons why it might tally.
It's also not compensated with more either, on average sufferers had less total capillaries. If we could measure this without a biopsy it could be diagnostically useful depending on whether other similar diseases show this too.
 
Back
Top Bottom